Este artigo está disponível apenas em inglês no momento.
AI in UK Healthcare: What NHS Trusts and Private Healthcare Providers Must Do
AI in clinical settings is regulated by MHRA as a medical device, subject to DSPT requirements, UK GDPR, and NHS governance frameworks. Here is the compliance landscape for UK healthcare AI.
Key Takeaways
AI used for clinical decision support — diagnostic assistance, risk stratification, treatment recommendation — is regulated by MHRA as Software as a Medical Device (SaMD) under UK Medical Devices Regulations 2002. UKCA marking is required before deployment in clinical settings.
NHS trusts must complete a Data Security and Protection Toolkit (DSPT) assessment covering AI tools that process patient data. The DSPT requires evidence that AI systems meet NHS data security standards before clinical deployment.
UK GDPR and the common law duty of confidentiality apply to all patient data processed by AI systems. Data Processing Agreements must be in place with AI vendors — NHS trusts are responsible for how AI vendors handle patient data.
Clinicians retain professional and legal responsibility for decisions made with AI assistance. The responsible clinician must understand AI outputs well enough to exercise professional judgement — following AI recommendations without understanding their basis does not satisfy the professional duty of care.
The NHS AI Lab's Evidence Standards Framework for Digital Health Technologies sets out what evidence is expected before AI adoption into NHS clinical pathways. Private providers are not formally bound but the standards represent best practice.
Clinical negligence liability for AI-assisted errors follows existing clinical negligence frameworks. Trusts and clinicians must demonstrate that AI-assisted decisions met the standard of a reasonably competent practitioner.
"Apenas para fins informativos. Este artigo não constitui aconselhamento jurídico, regulatório, financeiro ou profissional. Consulte um especialista qualificado para orientação específica."
The regulatory landscape for AI in UK healthcare
Healthcare AI in the UK sits at the intersection of medical device regulation (MHRA), data protection (UK GDPR, common law duty of confidentiality, NHS data security requirements), clinical governance and professional responsibility, and NHS procurement governance. Understanding which framework applies to which AI system is the starting point for building a defensible governance framework.
MHRA regulation of AI as a medical device
The MHRA regulates Software as a Medical Device (SaMD) under UK Medical Devices Regulations 2002, as amended post-Brexit. AI that is intended for diagnosis, prevention, monitoring, prediction, treatment, or alleviation of disease is likely to be regulated as a medical device. Most AI diagnostic and decision support tools fall into Class IIa or IIb, requiring notified body involvement. UKCA marking is required before placing the device on the UK market. Healthcare organisations should verify that clinical AI vendors hold appropriate UKCA marking before deployment.
NHS data security requirements
NHS organisations must complete annual DSPT assessments covering AI tools that process patient data. Key DSPT requirements for AI: evidence that data security has been assessed; confirmation that Data Processing Agreements are in place with AI vendors; and demonstration that patient data is handled in accordance with National Data Guardian standards. Access to NHS patient data for AI training and development is separately governed by NHS England's data access frameworks.
Clinical responsibility and professional obligations
The GMC, NMC, and Royal Colleges are clear that clinicians retain professional responsibility for decisions made with AI assistance. AI is an assistive tool — the responsible clinician must understand AI outputs well enough to evaluate them. Before deploying AI in a clinical pathway, trusts should ensure: clinicians receive adequate training on the tool's capabilities, limitations, and failure modes; a clinical lead is responsible for oversight; ongoing performance monitoring is in place; and AI-related clinical concerns have a clear reporting pathway.